Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. (vol 369, pg 559, 2007)

被引：0
|
作者：
Coombes, R. C.
Kilburn, L. S.
Snowdon, C. F.
机构：
来源：
LANCET | 2007年 / 369卷 / 9565期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：906 / 906
页数：1
相关论文
共 41 条
  • [1] Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
    Coombes, R. C.
    Kilburn, L. S.
    Snowdon, C. F.
    Paridaens, R.
    Coleman, R. E.
    Jones, S. E.
    Jassem, J.
    Van de Velde, C. J. H.
    Delozier, T.
    Alvarez, I.
    Del Mastro, L.
    Ortmann, O.
    Diedrich, K.
    Coates, A. S.
    Bajetta, E.
    Holmberg, S. B.
    Dodwell, D.
    Mickiewicz, E.
    Andersen, J.
    Lonning, P. E.
    Cocconi, G.
    Forbes, J.
    Castiglione, M.
    Stuart, N.
    Stewart, A.
    Fallowfield, L. J.
    Bertelli, G.
    Hall, E.
    Bogle, R. G.
    Carpentieri, M.
    Colajori, E.
    Subar, M.
    Ireland, E.
    Bliss, J. M.
    LANCET, 2007, 369 (9561): : 559 - 570
  • [2] Survival & safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment: A number needed to treat analysis based on the intergroup exemestane study (IES)
    Kilburn, L. S.
    Mundayat, R.
    Bliss, J. M.
    Coombes, C.
    Chirgwin, J.
    Chen, C.
    Fallowfield, L.
    Wang, Z.
    BREAST, 2009, 18 : S51 - S51
  • [3] Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)-a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen
    Bertelli, G.
    Hall, E.
    Ireland, E.
    Snowdon, C. F.
    Jassem, J.
    Drosik, K.
    Karnicka-Mlodkowska, H.
    Coombes, R. C.
    Bliss, J. M.
    ANNALS OF ONCOLOGY, 2010, 21 (03) : 498 - 505
  • [4] Quality of life in the intergroup exemestane study: A randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer
    Fallowfield, LJ
    Bliss, JM
    Porter, LS
    Price, MH
    Snowdon, CF
    Jones, SE
    Coombes, RC
    Hall, E
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) : 910 - 917
  • [5] Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study
    Mieog, J. Sven D.
    Morden, James P.
    Bliss, Judith M.
    Coombes, R. Charles
    van de Velde, Cornelis J. H.
    LANCET ONCOLOGY, 2012, 13 (04): : 420 - 432
  • [6] First mature survival analysis of the Intergroup Exemestane Study: A randomised trial in disease-free, postmenopausal patients with early breast cancer randomized to continue tamoxifen or switch to exemestane following an initial 2-3 years of adjuvant tamoxifen.
    Coombes, R. C.
    Paridaens, R.
    Jassem, J.
    Van de Velde, C. J.
    Delozier, T.
    Jones, S. E.
    Hall, E.
    Kilburn, L. S.
    Snowdon, C. F.
    Bliss, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 9S - 9S
  • [7] Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 152 - 152
  • [8] Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden
    Lundkvist, Jonas
    Wilking, Nils
    Holmberg, Stig
    Jonsson, Linus
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 102 (03) : 289 - 299
  • [9] Exemestane therapy after 2 to 3 years of tamoxifen therapy improved survival compared with 5 years of tamoxifen therapy alone
    Coombes, RC
    Hall, E
    Gibson, LJ
    ANNALS OF INTERNAL MEDICINE, 2005, 143 (11) : 824 - 824
  • [10] Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2–3 years treatment with tamoxifen in Sweden
    Jonas Lundkvist
    Nils Wilking
    Stig Holmberg
    Linus Jönsson
    Breast Cancer Research and Treatment, 2007, 102 : 289 - 299
12345